(Q60705896)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

U Jeppesen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

B B Rasmussen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

language of work or name

English

0 references

publication date

1 September 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

279-286

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Interaction between fluvoxamine and imipramine/desipramine in four patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Fluvoxamine-tricyclic antidepressant interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

A fluvoxamine-caffeine interaction study

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

inferred from DOI database lookup

7 January 2021

based on heuristic

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Inhibitors of imipramine metabolism by human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

A metabolite of paludrine with high antimalarial activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

The absorption and excretion of paludrine in the human subject.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990030-8

10.1016/S0009-9236(97)90030-8

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9333103%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference